Clinical Trial: Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma
Brief Summary: The purpose of this study is to determine whether TRC105 in combination with Bevacizumab is effective in the treatment of one patient with metastatic and refractory choriocarcinoma.
Detailed Summary:
Sponsor: Tracon Pharmaceuticals Inc.
Current Primary Outcome: Progression Free Survival [ Time Frame: one year ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Number of adverse events [ Time Frame: one year ]
- Severity of adverse events (CTCAE) v4 [ Time Frame: one year ]
Original Secondary Outcome: Same as current
Information By: Tracon Pharmaceuticals Inc.
Dates:
Date Received: March 5, 2015
Date Started: January 2015
Date Completion: November 2017
Last Updated: May 16, 2017
Last Verified: January 2016
